PATENT CLAIM ANALYSIS

Application Number: 15764687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "480000"]

Abstract:
Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, and allergic, autoimmune, and inflammatory disorders including hematological malignancies. In particular, the methods include administration of a BTK inhibitor and with one or more inhibitor. For example, the one or more inhibitor may be a JAK inhibitor, a ASK1 inhibitor, a BRD4 inhibitor or an MMP9 inhibitor.

Claim (Index 13):
A kit comprising:\n a pharmaceutical composition comprising a pharmaceutically effective amount of a BTK inhibitor, wherein the BTK inhibitor is 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical composition comprising a pharmaceutically effective amount of one or more inhibitor, wherein the inhibitor is selected from the group consisting a JAK inhibitor, an ASK1 inhibitor, a BRD inhibitor, and a MMP9 inhibitor, and instructions for use in treating a disease selected from the group of a cancer, allergic disorders, autoimmune diseases, and inflammatory diseases.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.61364
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15319740', '14135812', '15105372', '14254010', '14570655']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7557612843500231
- 35 USC 102 Novelty (BERT): 0.5085570590302558
- Combined Prediction Score: 0.7310408618180464
- Mean Citation Score: 247.382998
- Max Citation Score: 260.51425
- Similarity Product: 170.53219958046083

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test